New combo therapy tested for Tough-to-Treat cancers that have returned
NCT ID NCT03728361
Summary
This study is testing whether combining two existing drugs—nivolumab (an immunotherapy) and temozolomide (a chemotherapy)—can help control cancers that have come back or stopped responding to standard treatments. It is for adults with recurrent small-cell lung cancer or advanced neuroendocrine tumors that have spread. The main goal is to see if this combination can shrink tumors and for how long it can keep the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center-COHORT 1
Columbus, Ohio, 43210, United States
-
Ohio State University Comprehensive Cancer Center-COHORT 2
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.